NervGen Pharma Corp.
NGEN.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.64% | -24.51% | -5.30% | -20.58% | -20.68% |
| Total Depreciation and Amortization | -56.05% | -61.25% | -42.88% | -25.02% | -8.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -19.95% | -27.24% | -45.84% | 22.50% | 346.52% |
| Change in Net Operating Assets | 42.66% | 2.52% | 440.93% | -21.65% | 716.90% |
| Cash from Operations | -40.39% | -76.45% | -47.14% | -21.80% | 29.23% |
| Capital Expenditure | -- | -- | -- | 100.00% | 69.70% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 176.03% | 159.49% | 142.09% | 124.31% | -- |
| Cash from Investing | 174.46% | 157.12% | 141.16% | 123.77% | -1,965.96% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | -69.52% | -89.41% | 2,716.70% | 2,316.22% | 15.39% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 62.90% | 69.58% | -- | -1,163.80% | -1,228.69% |
| Cash from Financing | -71.28% | -91.64% | 2,861.01% | 2,812.73% | 4.85% |
| Foreign Exchange rate Adjustments | -234.26% | 26.98% | -139.54% | 97.89% | -47.73% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -199.91% | -225.28% | 154.49% | 149.46% | 110.62% |